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Socioeconomic inequalities 
in expenditures and income 
committed to the purchase of 
medicines in Southern Brazil
ABSTRACT
OBJECTIVE: To describe socioeconomic inequalities regarding the use, 
expenditures and the income committed to the purchase of medicines.
METHODS: A cross-sectional population-based study was carried out with 
1,720 adults living in the urban area of Florianópolis, Southern Brazil, in 2009. 
Cluster sampling was adopted and census tracts were the primary sampling 
units. Use of medicines and the expenditures incurred in their purchase in 
the past 30 days were investigated through interviews. Use, expenditures and 
the income committed concerning medicines were analyzed according to per 
capita family income, self-reported skin color, age and sex, adjusting for the 
complex sample.
RESULTS: The prevalence of medicine use was 76.5% (95%CI: 73.8; 79.3), 
higher among women and in older individuals. The mean expenditure on 
medicine was R$ 46.70, with higher values among women, whites, older 
individuals and among richer people. While 3.1% of the richest committed 
more than 15% of their income to purchasing medicine, that fi gure reached 
9.6% in the poorest group. The proportion of people that had to buy medicines 
after an unsuccessful attempt to obtain them in the public health system was 
higher among the poor (11.0%), women (10.2%) and the elderly (11.1%). A 
large part of the adults bought medicines contained in the National List of 
Essential Medicines (19.9%) or in the Municipal List of Essential Medicines 
(28.6%), with signifi cant differences according to gender, age and income.
CONCLUSIONS: There is socioeconomic, age and gender inequality in the 
income committed to the purchase of medicines, with worse conditions for 
the poor, older individuals and women.
DESCRIPTORS: Income. Health Expenditures. Pharmaceutical 
Preparations. Health Inequalities. Cross-Sectional Studies.
INTRODUCTION
The Brazilian health system has been legally universal, equitable and integral 
since the end of the 1980s. The Sistema Único de Saúde (SUS – National 
Health System), which was created in Brazil in 1990, has incorporated actions 
to consolidate its principles and guidelines, such as the guarantee of integral 
therapeutic assistance, including pharmaceutical assistance.
Brazil is one of the few countries in which free access to essential medicines is a 
right of the citizens, materialized by means of policies and strategies, like Relação 
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Nacional de Medicamentos Essenciais (RENAME – 
National List of Essential Medicines) and Relação 
Municipal de Medicamentos Essenciais (REMUME 
– Municipal List of Essential Medicines).4 Generic 
drugs were introduced in Brazil in 1999 to reduce the 
price of medicines and facilitate the access of the entire 
population to these inputs. In 2004, the federal govern-
ment launched Programa Farmácia Popular (Popular 
Drugstore Program), which aims to reduce the impact 
of medicines’ prices on the family budget based on the 
co-payment system, in which the public power pays 
approximately 90% of the medicine’s value and the 
citizen pays directly the rest.a
Despite the advancements in the sector’s public poli-
cies, they do not reach a large part of the population, 
mainly concerning the rational use of medicines, both in 
the private market and in the public sector.7 The global 
investment in health (public and private expenditures) 
was equivalent to 7.6% of the Brazilian gross domestic 
product in 2003,19 showing a lower participation of the 
public sector in this proportion (45.3%), a value that 
is close to the one observed in countries with non-
universal health systems.19 The low public investment in 
health causes higher private expenditures in this sector, 
including drug expenditures.
Drug expenditure represents the largest part of the 
private expenditures on health among the poor. The 
medicines’ weight in the total health expenditures is 
inversely proportional to income, according to a litera-
ture review in 54 low-income countries.16 Similarly, 
medicines have had the largest share of responsi-
bility for health expenditures in Brazil, reaching 
approximately 47% of the total expenditures.3 Income 
committed to drug expenditure, especially when it is 
not planned, can lead families to even greater health 
risks, like the reduction in the purchase of food prod-
ucts, and make them become more susceptible to health 
problems, or, by the economic order, make families 
become poorer or even indigent.b
Brazilian population-based studies have shown that 
the mean expenditure on medicines in absolute fi gures 
is higher among older men12 and increases as income 
increases.3 The SUS assumes the largest part of the 
global drug expenditures, mainly among the poor, while 
the rich present more private expenditures.5 In spite 
of this, data from Pesquisa Nacional por Amostra de 
Domicílios 1998 (National Household Sample Survey) 
presented more income committed to the purchase of 
medicines among the poor, transposing differences 
between groups and confi guring it as inequity.15
a Agência Nacional de Vigilância Sanitária - ANVISA. Vigilância sanitária: guia didático. Brasília (DF): Ministério da Saúde; 2002.
b Instituto Brasileiro de Geografi a e Estatística. Pesquisa de Orçamentos Familiares 2002-2003. Rio de Janeiro: IBGE; 2004.
c Instituto Brasileiro de Geografi a e Estatística - IBGE. População brasileira [cited 2009 Feb 10]. Available from: http://www.ibge.gov.br
d Programa das Nações Unidas para o Desenvolvimento - PNUD. Atlas do desenvolvimento humano no Brasil. Brasília (DF); 2003.
The aim of the present study was to describe socioeco-
nomic inequalities concerning the use, expenditures 
and income committed to the purchase of medicines.
METHODS
Cross-sectional population-based study with 2,016 adults 
aged 20-59 years from the urban area of Florianópolis 
(Southern Brazil), carried out between August 2009 
and January 2010. The study was called EpiFloripa. 
Florianópolis is the capital city of the State of Santa 
Catarina. It is a medium-sized municipality, with popu-
lation estimated at 408,163 inhabitants in 2009.c In the 
most recent national census (year 2000), Florianópolis 
presented per capita income of R$ 701.42 (equivalent to 
US$ 354.25), Gini index of 0.57 and municipal Human 
Development Index (MHDI) of 0.875, the highest one 
among the Brazilian capital cities.d
The study’s target population corresponded to 249,530 
people, equivalent to 61.1% of the total population of 
the municipality.c 
The parameters to the fi nal sample were: prevalence 
of drug expenditures of 50%, sample error of four 
percentage points, and a 95% confi dence interval. 
A design effect of 2 was used, 10% were added for 
possible losses or refusals and 20% to control for 
confounding factors. This sample was enough to esti-
mate the outcome of any magnitude considering the 
same sample error.
Two-stage sampling was performed. The fi rst stage 
was formed by the census tracts defi ned by Instituto 
Brasileiro de Geografi a e Estatística (IBGE – Brazilian 
Institute of Geography and Statistics) for statistical 
purposes. The units of the second stage were the house-
holds included in the selected census tracts. The study’s 
unit of analysis was the adult individual. All the adult 
inhabitants of the selected households were eligible for 
the interview, except for institutionalized individuals 
or those unable to answer the study’s questionnaire 
(bedridden or with some physical or mental disability).
The mean income of the heads of households was 
observed in the 420 urban census tracts according to 
the 2000 Census and the values ranged from R$ 192.80 
to R$ 13,209.50. The sectors were organized in an 
increasing income order and stratifi ed in deciles. Sixty 
census tracts were drawn, with systematic selection of 
six sectors in each income decile. With a minimum of 
61 households and a maximum of 810, the coeffi cient 
of variation of occupied households across sectors was 
55%. In order to reduce it, some census tracts were 
merged and others were divided; thus, 63 census tracts 
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were obtained with a coeffi cient of variation of 32%. 
Eighteen households were systematically drawn in each 
of these geographical units.
Data collection was performed by 35 female inter-
viewers. They had completed High School and were 
fully available to conduct the fi eldwork. The Personal 
Digital Assistant (PDA) was used to register and store 
data. Losses were considered adult inhabitants of drawn 
households that were not found after at least four visits, 
one on a weekend and another in the night period.
The quality control of the answers was performed on 
a weekly basis through revision and checking of 15% 
of the interviews, selected by means of a draw in each 
sector. Key information contained in the questionnaire 
was verifi ed by telephone by the fi eld supervisors. 
Analyzing the agreements, the kappa value varied 
from 0.6 to 1.0.
The outcomes were the use of medicines, expenditures 
and the income committed to the purchase of them 
during 30 days before the interview. The socioeco-
nomic classifi cation was performed according to the 
interviewees’ per capita family income (stratifi ed in 
quintiles). Information on self-reported skin color was 
also utilized (white, mixed-color, black, indigenous 
and yellow; the last two were excluded from this 
analysis due to the small number of people), as well 
as gender and age in complete years (20 to 29; 30 to 
39; 40 to 49 and 50 to 59).
The question that guided the study was: “In the last 30 
days did you take any medicine?”. The names, dosages 
and pharmaceutical presentation of the medicines were 
asked, as well as the form of acquisition (SUS; commer-
cial drugstore; the person already had it at home or was 
given by someone). The number of medicines used, 
the purchase of medicines because it was not possible 
to obtain them from the SUS, and their presence on 
RENAME and REMUME were analyzed.
To calculate the drug expenditures, information referring 
to the last 30 days and self-reported values described in 
reais (Brazilian currency) were used. The value of the 
income committed to the purchase of medicines was 
obtained by the division of the reported expenditure by 
the per capita family income. Then, the quotient was 
multiplied by 100 and the value was expressed in the 
form of percentage. For this calculation, 24 people who 
had no income were excluded. The variable income 
commitment was categorized according to cutoff points 
equal to ≥ 5%, ≥ 10% and ≥ 15%.
Table 1. Sample according to sociodemographic variables, prevalence of medicine use and crude and adjusted prevalence 
ratios. Florianópolis, Southern Brazil, 2009.
Variablea









Male 761 44.5 65.9 (61.9;69.9) 1 1
Female 959 55.5 85.0 (82.2;87.9) 1.29 (1.21;1.37) 1.29 (1.21;1.37)
Age (years) 
20 to 29 540 32.7 73.9 (69.9;77.8) 1 1
30 to 39 392 22.9 72.8 (68.2;77.4) 0.98 (0.92;1.05) 0.98 (0.91;1.04)
40 to 49 438 25.0 79.5 (75.4;83.5) 1.08 (1.01;1.15) 1.05 (0.98;1.12)
50 to 59 350 19.4 81.6 (77.7;85.5) 1.10 (1.03;1.18) 1.07 (1.00;1.15)
Race/Skin colora
White 1.444 85.8 76.5 (73.4;79.6) 1 1
Mixed 147 9.1 77.3 (69.6;85.1) 1.01 (0.91;1.13) 1.04 (0.93;1.17)
Black 87 5.1 74.6 (63.3;85.8) 0.97 (0.85;1.11) 1.00 (0.89;1.12)
Per capita family income in quintiles (R$)c
Quintile 1 337 20.0 76.0 (71.0;81.0) 0.98 (0.87;1.08) 0.96 (0.87;1.07)
Quintile 2 353 19.8 74.2 (70.6;77.9) 0.96 (0.88;1.04) 0.96 (0.88;1.04)
Quintile 3 321 18.7 75.8 (70.8;80.8) 0.98 (0.89;1.07) 0.98 (0.89;1.07)
Quintile 4 351 21.9 79.4 (74.4;84.3) 1.02 (0.95;1.10) 1.02 (0.94;1.10)
Quintile 5 323 19.6 77.5 (71.8;83.2) 1 1
TOTAL 1.720 76.5 (73.8;79.3)
a The variable with the lowest n was skin color (n=1678)
b Adjusted by socioeconomic and demographic variables
c US$1 is equivalent to R$1.75
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The statistical analyses were performed using the Stata 
svy commands to correct the design effect of complex 
samples and incorporate the sample weights. It is avail-
able in the program Stata version 9.0. The analyses 
of use, expenditures and income commitment were 
carried out according to income quintile, skin color, age 
and gender. Crude and adjusted prevalence ratios were 
calculated by means of Poisson regression, considering 
the demographic and socioeconomic variables for the 
outcomes: proportion of use of medicines, acquisition 
of at least one medicine through the SUS, purchase of 
medicines not obtained through the SUS, expenditures 
on medicines from RENAME and expenditures on 
medicines from REMUME. The socioeconomic and 
demographic variables were adjusted among them-
selves in the adjusted model. To test the difference 
between means, the Mann Whitney and Kruskall-
Wallis tests were employed.
The calculation of the sample was performed in EpiInfo 
6.04.
The study was approved by the Research Ethics 
Committee of Universidade Federal de Santa Catarina 
(Process no. 351/2008).
RESULTS
The response rate was 85.3% (n = 1,720). The mean 
age of the interviewees was 38 years (standard-
deviation – SD = 11.6) and 55.5% were women. The 
prevalence of medicines use during 30 days before 
the interview was 76.5%, 29% higher among women 
(PR: 1.29; 95% CI: 1.21;1.39) and 7% higher in older 
adults when compared to younger adults (PR: 1.07; 
95%CI: 1.00;1.15) in the adjusted analysis. No statisti-
cally signifi cant differences were observed in the use 
of medicines among the income and skin color strata 
(Table 1). Approximately one third of the adults who 
used medicines in the past 30 days used only one, 
approximately half used two, ¼ reported the use of three 
and a little less than 10% used four or more medicines.
The mean expenditure was R$ 46.70 (median = R$ 
10.00), varying from zero to R$ 920.00. The spent 
values were 60% higher among the women and 
increased according to the individuals’ income, approxi-
mately fi ve times higher among the richer ones (Q5) 
when compared to the poorer ones (Q1). Higher expen-
ditures were observed among older people (approxi-
mately three times higher in the older individuals when 
compared to the younger ones). White individuals 
(70% more) and mixed-color individuals (50% more) 
Table 2. Mean expenditure and proportion of income spent with medicines in the 30 days before the interview, according to 









Mean proportion of 







Male 35.3 1.0 3.0 1.0
Female 55.6 1.6 5.8 1.9
Age (years) <0.001** <0.001**
20 to 29 26.8 1.0 3.5 1.0
30 to 39 48.7 1.8 5.1 1.4
40 to 49 48.9 1.8 4.3 1.2
50 to 59 72.5 2.7 5.8 1.6
Skin color 0.002** 0.175**
White 48.4 1.7 4.2 1.0
Mixed-color 41.4 1.5 6.9 1.6
Black 28.2 1.0 6.2 1.5
Per capita family income in quintiles <0.001b 0.002b
Quintile 1 18.9 1.0 7.3 2.7
Quintile 2 24.2 1.3 4.4 1.6
Quintile 3 37.8 2.0 4.3 1.6
Quintile 4 63.3 3.3 4.2 1.6
Quintile 5 90.1 4.8 2.7 1.0
Total 46.7 4.6
*Mann Whitney Test; **Kruskal-Wallis Test
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presented higher expenditures on medicines than black 
individuals (Table 2).
The income committed to the purchase of medicines 
was almost three times higher among the poorer indi-
viduals (Q1) when compared to the richer ones (Q5). 
While in the fi rst income quintile people committed, 
on average, 7.3% of their income to the purchase of 
medicines, in the richest quintile the proportion was of 
2.7% (Table 2). More income was committed among the 
women (90% more) and among the older individuals 
(60% more among individuals aged 50 – 59 years 
compared to those aged 20 – 29 years) (Table 2).
Figure 1 presents the prevalence of people who spent 
any value with the purchase of medicines and the 
proportion of people who committed values equal to 
or higher than 5%, 10% and 15% of their income to the 
purchase of medicines, according to the quintiles of per 
capita family income. Approximately 70% of the richer 
ones (Q5) committed some of their income to expen-
ditures on medicines, a proportion that is signifi cantly 
higher than in the other groups (Figure 1A). However, 
the proportion of people who committed 5% or more of 
their income to expenditures on medicines was much 
higher among the poorer individuals (Q1) (Figure 
1B). This difference was more signifi cant when higher 
income commitments were considered. While 6.5% of 
the richer individuals (Q5) committed 10.0% or more 
of their income to the purchase of medicines, among 
the poorer ones, 14.6% presented this situation (Figure 
1C). When the focus was on commitment equal to or 
higher than 15%, 9.6% of the poorer individuals (Q1) 
were in this condition, compared to 3.1% of the richer 
individuals (Q5) (Figure 1D).
Table 3 presents differences related to the purchase of 
medicines in the SUS according to gender, age, skin 
color and per capita family income. Approximately 
one out of every fi ve people obtained at least one 
medicine in the SUS, a signifi cantly higher value among 
the poorer individuals (PR: 6.20 95%CI 3.50;10.97), 
women (PR: 1.56 95%CI 1.18;2.06), older individuals 
(PR: 1.76 95%CI 1.29;2.42) and the blacks (PR: 1.44 
Table 3. Proportion of people who obtained medicines through the Sistema Único de Saúde (National Health System), who 
purchased at least one medicine not obtained through the SUS, who presented expenditures on medicines from Relação 
Nacional de Medicamentos Essenciais (National List of Essential Medicines)and from Relação Municipal de Medicamentos 



















Male 14.2 5.3 15.4 22.8
Female 24.3 10.4 23.6 33.3
Age (years) 
20 to 29 16.4 5.3 16.2 26.3
30 to 39 19.1 8.5 19.2 25.4
40 to 49 20.0 9.0 20.5 29.1
50 to 59 26.2 11.3 26.3 35.7
Race/Skin color
White 18.2 7.9 20.8 29.4
Mixed 24.6 7.1 17.0 24.9
Black 35.3 9.1 12.9 23.2
Per capita family income in quintiles (in R$)a
Quintile 1 37.1 10.6 15.4 24.4
Quintile 2 27.1 9.4 19.6 25.3
Quintile 3 16.1 9.2 18.7 28.9
Quintile 4 14.0 7.3 22.3 31.1
Quintile 5 5.5 4.6 24.0 33.8
Total 19.8 8.1 19.9 28.6
a US$1 is equivalent to R$1.75
SUS: Sistema Único de Saúde (National Health System)
RENAME: Relação Nacional de Medicamentos Essenciais (National List of Essential Medicines)
REMUME: Relação Municipal de Medicamentos Essenciais (Municipal List of Essential Medicines)
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95%CI 1.08;1.93) (Table 4). A higher proportion of 
women, older people and poorer individuals needed to 
purchase medicines after trying unsuccessfully to obtain 
them through the SUS. No difference was observed 
regarding skin color. A large proportion of people 
purchased medicines that compose the lists RENAME 
and REMUME (19.9% and 28.6%, respectively), 
mainly women, older individuals and richer individuals 
in the crude and adjusted analyses (Table 4).
DISCUSSION
Women and older individuals use more, spend more and 
commit more income to drug expenditures compared 
to men and to younger people. Individuals who 
self-reported their skin color as black presented less 
expenditures on medicines than white individuals. An 
important socioeconomic inequality was observed in 
drug expenditures and in the income committed to the 
purchase of medicines, i.e., the poorer the individual, 
the higher the income committed, but the richer the 
individual, the higher the expenditures on medicines.
The prevalence of medicines use was higher than the 
ones observed in other national studies with adults, 
whose prevalences vary from 49.7%2 to 69.9%,17 and 
the same occurs in international studies (from 36.8%13 
to 67.4%).11 The differences in prevalences may derive 
from differences in the analyzed age groups and in the 
recall period. If, on the one hand, a longer recall time 
can increase the exposure to the use of medicines, on 
the other hand it can increase the memory bias, mainly 
in the population that does not use medicines in a 
continuous way.6 Furthermore, differences in the phar-
maceutical policies adopted in different countries may 
infl uence the behavior of medicines use and may partly 
explain the distinct prevalences when we compare the 
national and international panoramas.
Higher utilization of medicines among women and 
older individuals corroborate the findings of the 
literature,7,9,11 which also point to higher concern about 
health and higher utilization of the health services in 
the female sex.10 It is expected that individuals are 
affected by a higher number of chronic diseases as 
age advances and, consequently, use more the health 
services. The combination of these factors directly 
influences the increase in the use of medicines.8 
Additionally, the medicalization of health adopted by 
a large part of professionals and institutions, besides 
health actions and programs that are specifi c to women, 
like adolescents, pregnant women and puerperal 
women, contribute to explain this scenario.14
Table 4. Crude and adjusted prevalence ratios of people who obtained medicines through the Sistema Único de Saúde (National 
Health System), who purchased at least one medicine not obtained through the SUS, who presented expenditures on medicines 
from Relação Nacional de Medicamentos Essenciais (National List of Essential Medicines)and from Relação Municipal de 
Medicamentos Essenciais (Municipal List of Essential Medicines),according to socioeconomic and demographic variables. 
Florianópolis, Southern Brazil, 2009.
Variables
Acquisition of at 
least one medicine 
through the SUS
Purchase of medicines 









Crude PRa (95%CI) 1.71 (1.30;2.24) 1.95 (1.34;2.83) 1.54 (1.21;1.95) 1.46 (1.25;1.72)
Adjusted PRa (95%CI) 1.56 (1.18;2.06) 1.92 (1.33;2.77) 1.57 (1.22;2.03) 1.46 (1.25;1.71)
Age (years) 
Crude PRb (95%CI) 1.59 (1.18;2.15) 2.15 (1.26;3.66) 1.62 (1.20;2.18) 1.36 (1.11;1.66)
Adjusted PRb (95%CI) 1.76 (1.29;2.42) 2.52 (1.46;4.33) 1.55 (1.16;2.06) 1.25 (1.02;1.53)
Race/Skin color
Crude PRc (95%CI) 1.94 (1.36;2.76) 1.14 (0.52;2.51) 0.62 (0.34;1.13) 0.79 ( 0.54;1.16)
Adjusted PRc (95%CI) 1.44 (1.08;1.93) 1.10 (0.47;2.58) 0.74 (0.40;1.34) 0.84 (0.56;1.26)
Per capita family income in quintiles 
Crude PR (95%CI) 6.72d (3.77;11.96) 2.32d (1.18;4.55) 1.56e (1.10;2.20) 1.38e (1.08;1.77)
Adjusted PR((95%CI) 6.20d (3.50;10.97) 2.08d (1.00;4.33) 1.44e (1.01;2.06) 1.37e (1.07;1.75)
a Ratio between W/M;
b Ratio between 50-59/20-29
c Ratio between Black/White;
d Ratio between Q1/Q5
e Ratio between Q5/Q1
SUS: Sistema Único de Saúde (National Health System)
RENAME: Relação Nacional de Medicamentos Essenciais (National List of Essential Medicines)
REMUME: Relação Municipal de Medicamentos Essenciais (Municipal List of Essential Medicines)
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The expenditures mean was higher among women 
and older individuals, accompanying the greater use 
of these inputs in these groups, and white individuals 
spent more than black individuals, similarly as found in 
the United States,20 but the association lost signifi cance 
after adjustment.
Drug expenditures were higher among the richer indi-
viduals, which suggests higher availability of fi nancial 
resources and also the possibility that the SUS has a more 
comprehensive coverage among the poorer individuals, 
potentially minimizing the absolute expenditures of 
this group.e The lower expenditures among the poorer 
individuals may be explained by the expansion of health 
programs in the SUS, like Farmácia Básica (Basic 
Drugstore), Estratégia da Saúde da Família (Family 
Health Strategy) and Farmácia Popular (Popular 
Drugstore), as well as the changes in prices of goods 
and services and the income of poor families, which 
may reduce or even eliminate the health expenditures to 
allocate them to other goods and services.c Besides, the 
higher absolute expenditures on the acquisition of these 
products among the greatest consumers, i.e., women and 
older individuals, is coherent, confi rming the fi ndings 
of the national literature.1
The inequality in the income committed to the purchase 
of medicines was worse to the poorer individuals. When 
the committed income was analyzed in at least 10% and 
15% of the total per capita income, the difference in the 
committed income was 2.2 times and 3.1 times higher 
in the poorer individuals when compared to the richer 
ones. This was also observed in the literature when 
the general health expenditures were considered, with 
higher income commitment among women, the poorer 
individuals and the older ones.18
The higher commitment of health expenditures 
can become catastrophic if the health expenditure 
e Diniz BPC, Servo LMS, Eirado M, Piola SF. Gasto das famílias com saúde no Brasil: evolução e debate sobre gasto catastrófi co. In: Silveira 
FG, Servo LMS, Menezes T, Piola SF, organizadores. O gasto e consumo das famílias brasileiras contemporâneas. Brasília (DF): IPEA; 2007. 
p.143-166.
Figure 1. Per capita family income committed to drug expenditures according to the population’s per capita income quintiles: 
(A) Income commitment 0%; (B) Income commitment 5%; (C) Income commitment 10% and (D) Income commitment 
15%. Florianópolis, SC, 2009.
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represents at least 40% of the family income after the 
payment of their subsistence expenditures.20 In a study 
conducted among 59 countries investigated in relation 
to catastrophic health expenditures, Brazil presented 
the second highest prevalence of families in this situa-
tion (10.3%), behind Vietnam (10.5%).21 Of the health 
expenditures, those directed at the purchase of medi-
cines are among the most signifi cant.3
The results of the present study and the representa-
tion of medicines in the catastrophic expenditures 
show the importance of the State’s protection against 
these expenses due to the implications deriving from 
this process, like, for example, the non-utilization or 
the underutilization of medicines, interfering in the 
possibility of adequate treatment, cure, aggravation 
or health complications. The State’s role refers to the 
attempt to reduce the fi nancial obstacle, minimized by 
the availability or the reduction in medicines’ prices. 
Also, there is the role of the prescriber, who should 
consider the user’s capacity to pay and the availability 
of medicines in the public sector at the moment of the 
prescription.13 In addition, macroeconomic and social 
measures are fundamental, so as to impact the market 
of consumption and access to goods and services, like 
better income distribution, the access to public health 
services and general life conditions.
The studied sample presents external validity for 
the adult population residing in the urban area of 
Florianópolis. The uniform distribution of the losses 
in the family income deciles contributed to this condi-
tion of sample inference. The distribution by sex and 
age group was similar to the one found in the IBGE 
estimates for the adult population of the municipality 
for the year of 2009.
The potential memory bias involved in the self-reported 
data, like the use of medicines and the expenditures on 
the purchase of the products in the 30 days before the 
interview can be considered a limitation of the study. 
To minimize it, the interviewees were asked to provide 
prescriptions, packages and/or the description leafl et of 
medicines utilized in the past 30 days.
Considering the high impact of the private drug 
expenditure on people’s budget and the potential of 
minimization of this phenomenon through the SUS, 
the better utilization and organization of RENAME 
and REMUME might represent important mechanisms 
to reduce private expenditures regarding the public 
policies, as approximately 50% of the people do not 
use the medicines they need because they do not have 
access to them through the SUS.f Pharmaceutical 
policies that promote the rational use of the medicines 
should be implemented, improving health assistance 
and reducing drug expenditures.
f Ministério da Saúde. Acesso aos medicamentos, compras governamentais e inclusão social. Brasília (DF); 2003.
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